Top Markets
#1 Pleasing Gold Pleasing Gold +1,498.45%
#2 Ontology Gas Ontology Gas +151.18%
#3 PulseChain PulseChain +57.64%
#4 ConstitutionDAO ConstitutionDAO +37.98%
#5 BOOK OF MEME BOOK OF MEME +31.10%
#6 Neiro Neiro +29.12%
#7 Collect on Fanable Collect on Fanable +28.84%
#8 Pump.fun Pump.fun +27.30%
#9 Unit Pump Unit Pump +27.30%
#10 Ontology Ontology +27.09%
Coin of the day
Pleasing Gold Pleasing Gold
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
LianBio LianBio

LianBio

LIAN
Kedudukan dalam Saham #25844
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Harga Saham
$0.42275
Disegerakkan terakhir: 2025-07-14
Modal Pasaran
$45.81M
Perubahan (1 hari)
-0.89%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan LianBio (LIAN)

Kategori

Healthcare
Pendapatan untuk LianBio (LIAN)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini LianBio, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi LianBio dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US